2017
DOI: 10.1111/aos.13381
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Ranibizumab PRN resulted in greater visual acuity (VA) gains in macular oedema following BRVO compared with single-dose dexamethasone over a 6-month study period, observed from month 3, when administered according to their European label. In clinical practice, retreatment with dexamethasone may be required prior to this point.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
80
1
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 52 publications
(86 citation statements)
references
References 29 publications
4
80
1
1
Order By: Relevance
“…Both studies demonstrated a superior effect of ranibizumab over DEX with regard to visual outcome after 6 months when used according to the European labels (Hoerauf et al 2016;Hattenbach et al 2018). Both studies demonstrated a superior effect of ranibizumab over DEX with regard to visual outcome after 6 months when used according to the European labels (Hoerauf et al 2016;Hattenbach et al 2018).…”
Section: Discussionmentioning
confidence: 94%
See 4 more Smart Citations
“…Both studies demonstrated a superior effect of ranibizumab over DEX with regard to visual outcome after 6 months when used according to the European labels (Hoerauf et al 2016;Hattenbach et al 2018). Both studies demonstrated a superior effect of ranibizumab over DEX with regard to visual outcome after 6 months when used according to the European labels (Hoerauf et al 2016;Hattenbach et al 2018).…”
Section: Discussionmentioning
confidence: 94%
“…The statistical analysis was performed analogously to the core studies (Hoerauf et al 2016;Hattenbach et al 2018). All variables were analysed descriptively.…”
Section: Statistical Analysesmentioning
confidence: 99%
See 3 more Smart Citations